Kimberly-Clark Corporation (KMB)
NASDAQ: KMB · Real-Time Price · USD
98.23
+0.38 (0.39%)
At close: Apr 27, 2026, 4:00 PM EDT
98.18
-0.05 (-0.05%)
After-hours: Apr 27, 2026, 4:11 PM EDT

Kimberly-Clark Earnings Call Transcripts

Fiscal Year 2026

  • A major transformation has driven strong organic growth, margin expansion, and innovation-led market share gains. The Powering Care strategy, digital transformation, and operational excellence position the company for accelerated growth and value creation, especially with the Kenvue acquisition closing in 2026.

  • AGM 2026

    Stockholders approved the issuance of common stock as part of a merger agreement, with final results to be filed with the SEC. Only the issuance proposal was considered, and questions from stockholders will be answered by email.

Fiscal Year 2025

  • Delivered strong volume-plus-mix growth and share gains in key markets, with 2026 guidance targeting margin expansion, innovation-driven growth, and resilience despite competitive and channel headwinds. Kenvue acquisition and productivity gains are expected to further enhance performance.

  • Powering Care strategy drove innovation-led growth, margin expansion, and strong cash flow in 2025, with continued momentum into 2026. Pending Kenvue acquisition and joint venture with Suzano are expected to accelerate growth, deliver synergies, and enhance shareholder value.

  • The conference detailed the strategic rationale for acquiring Kenvue, emphasizing synergy opportunities, operational efficiency, and portfolio complementarity. Management outlined robust integration plans, a disciplined approach to brand and portfolio management, and confidence in delivering top-tier growth and margins post-deal.

  • M&A Announcement

    A transformational merger will create a global health and wellness leader with $32B in annual revenue and $7B in EBITDA, leveraging complementary portfolios and geographic strengths. The deal, valued at $48.7B, targets $2.1B in synergies and is expected to close in H2 2026, with a focus on innovation, operational discipline, and long-term value creation.

  • Delivered strong Q3 results with continued volume plus mix-led growth and margin expansion, driven by innovation and premiumization across all channels. Outlook remains positive, with margin targets and EPS growth expected post-IFB transaction.

  • Transformation momentum continues with Q3 organic net sales up 2.5% and strong productivity gains. Despite headwinds from divestitures, tariffs, and currency, the business is on track for low single-digit profit and EPS growth for 2025.

  • Transformation to a consumer-focused, higher-margin portfolio is accelerating progress toward 2030 targets, with reduced earnings volatility and strong productivity gains. Increased digital marketing and innovation are driving brand growth and market share, while cost savings and operational improvements support a positive financial outlook.

  • The company is advancing its transformation into a focused personal care and wellness leader, accelerating innovation, premiumization, and digital brand building. Strong productivity, portfolio reshaping, and global execution are driving growth, with financial targets on track and further gains expected as new strategies and partnerships take hold.

  • Second quarter results showed strong organic sales growth, robust volume, and global share gains, driven by innovation and effective portfolio focus. Outlook remains positive with continued volume/mix-led growth, increased brand investment, and improved margin targets.

  • Management highlighted progress in growth, innovation, and operational efficiency, with a focus on premiumization and global supply chain improvements. Despite category slowdown and tariff impacts, guidance remains volume and mix-driven, with continued investment in innovation and brand building.

  • AGM 2025

    The meeting highlighted a strong 2024 performance, exceeding growth targets and returning $2.6 billion to shareholders. All board nominees and proposals were approved, and strategic transformation initiatives were advanced.

  • Q1 results were in line with profitability expectations but organic sales growth lagged due to softer category growth, fewer shipping days, and tariff headwinds. Guidance was revised to flat EPS and operating profit, with continued investment in innovation and supply chain transformation.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Powered by